DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX) in a research note released on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Stock Down 5.9 %

Shares of DRRX stock opened at $0.85 on Tuesday. DURECT has a 52-week low of $0.48 and a 52-week high of $1.88. The stock’s 50-day moving average price is $1.30 and its 200 day moving average price is $1.36. The stock has a market capitalization of $26.41 million, a PE ratio of -1.39 and a beta of 1.13.

Institutional Investors Weigh In On DURECT

A number of institutional investors have recently added to or reduced their stakes in DRRX. International Assets Investment Management LLC boosted its stake in shares of DURECT by 41.3% during the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after acquiring an additional 6,300 shares in the last quarter. Accredited Investors Inc. purchased a new stake in shares of DURECT during the 2nd quarter worth approximately $113,000. Geode Capital Management LLC boosted its stake in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 14,658 shares in the last quarter. Finally, Richmond Brothers Inc. boosted its stake in shares of DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares in the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.